Air hunger, unwelcome guests, clogged pipes and idiopathic inflammatory myositis: Can we do better?

Respirology

Volumn 17, Issue 3, 2012, Pages 391-392

  Fernández Pérez, Evans R ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

coronary artery disease; infection; interstitial; lung disease; myositis

Indexed keywords

ANTIBIOTIC AGENT; COLLAGEN; CORTICOSTEROID; CYTOCHROME; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MUSCLE ENZYME; RIBONUCLEOPROTEIN ANTIBODY; SYNTHETASE;

ANTISYNTHETASE SYNDROME; ARTHRITIS; ASPIRATION PNEUMONIA; ATHEROSCLEROSIS; AUTOPSY; B LYMPHOCYTE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC LUNG DISEASE; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; EDITORIAL; ELECTROMYOGRAPHY; FEVER; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LUNG BIOPSY; LUNG DISEASE; MORBIDITY; MYOPATHY; MYOSITIS; PATHOGENESIS; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RECURRENT ASPIRATION; RISK FACTOR; RISK MANAGEMENT; RNA SYNTHESIS; T LYMPHOCYTE;

CAUSE OF DEATH; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; POLYMYOSITIS; RESPIRATORY TRACT DISEASES;

EID: 84859063263     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02138.x     Document Type: Editorial

References (24)

1. Okada S, Weatherhead E, Targoff IN, et al,. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003; 48: 2285-93.
2. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al,. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur. Respir. J. 2003; 22: 245-50.
3. Ito M, Kaise S, Suzuki S, et al,. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin. Rheumatol. 1999; 18: 462-7.
4. O'Hanlon TP, Rider LG, Mamyrova G, et al,. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 2006; 54: 3670-81.
5. Chinoy H, Salway F, Fertig N, et al,. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 2006; 8: R13.
6. Dalakas MC, Hohlfeld R,. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
7. Gunawardena H, Betteridge ZE, McHugh NJ,. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009; 48: 607-12.
8. Fischer A, Swigris JJ, du Bois RM, et al,. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir. Med. 2009; 103: 1719-24.
9. Nishikai M, Reichlin M,. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 1980; 23: 881-8.
10. Yamadori I, Fujita J, Kajitani H, et al,. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/ dermatomyositis. Rheumatol. Int. 2001; 21: 89-93.
11. Englund P, Wahlstrom J, Fathi M, et al,. Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 2007; 56: 372-83.
12. Maldonado F, Patel RR, Iyer VN, et al,. Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology 2012; 17: 166-171.
13. Solomon J, Swigris JJ, Brown KK,. Myositis-related interstitial lung disease and antisynthetase syndrome. J. Bras. Pneumol. 2011; 37: 100-9.
14. Ideura G, Hanaoka M, Koizumi T, et al,. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir. Med. 2007; 101: 1406-11.
15. Fujisawa T, Suda T, Nakamura Y, et al,. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J. Rheumatol. 2005; 32: 58-64.
16. Marie I, Hachulla E, Cherin P, et al,. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005; 53: 155-65.
17. Marie I, Menard JF, Hachulla E, et al,. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin. Arthritis Rheum. 2011; 41: 48-60.
18. Yamasaki Y, Yamada H, Yamasaki M, et al,. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007; 46: 124-30.
19. Kameda H, Nagasawa H, Ogawa H, et al,. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J. Rheumatol. 2005; 32: 1719-26.
20. Denbow CE, Lie JT, Tancredi RG, et al,. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum. 1979; 22: 1088-92.
21. Lundberg IE,. The heart in dermatomyositis and polymyositis. Rheumatology 2006; 45 (Suppl. 4): iv18-21.
22. Peters MJ, Symmons DP, McCarey D, et al,. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 2010; 69: 325-31.
23. Maradit-Kremers H, Nicola PJ, Crowson CS, et al,. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 52: 722-32.
24. Levy MM, Dellinger RP, Townsend SR, et al,. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit. Care Med. 2010; 38: 367-74.